Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?

Khasraw M, Dun MD, Arrillaga-Romany I, Verhaak RGW, Bouffet E, Hansford JR, Singh K, Mueller S, Koschmann C, Wen PY

DOI: 10.1093/neuonc/noag117
Published: 2026 Aug 1
Container: Neuro-oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/neuonc/noag117,
  title = {Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?},
  author = {Khasraw M and Dun MD and Arrillaga-Romany I and Verhaak RGW and Bouffet E and Hansford JR and Singh K and Mueller S and Koschmann C and Wen PY},
  year = {2026},
  journal = {Neuro-oncology},
  doi = {10.1093/neuonc/noag117},
  url = {https://doi.org/10.1093/neuonc/noag117}
}

RIS

TY  - JOUR
TI  - Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?
AU  - Khasraw M
AU  - Dun MD
AU  - Arrillaga-Romany I
AU  - Verhaak RGW
AU  - Bouffet E
AU  - Hansford JR
AU  - Singh K
AU  - Mueller S
AU  - Koschmann C
AU  - Wen PY
PY  - 2026
JO  - Neuro-oncology
DO  - 10.1093/neuonc/noag117
UR  - https://doi.org/10.1093/neuonc/noag117
ER  -

APA

M, K., MD, D., I, A., RGW, V., E, B., JR, H., K, S., S, M., C, K., & PY, W. (2026). Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?. Neuro-oncology. https://doi.org/10.1093/neuonc/noag117

Source records

pubmed · retrieved 2026-09-26T03:25:48.217Z
europe-pmc · retrieved 2026-09-26T03:25:48.202Z